Comparative Pharmacology
Head-to-head clinical analysis: AVIANE 28 versus AVLAYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVIANE 28 versus AVLAYAH.
AVIANE-28 vs AVLAYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol is an estrogen, levonorgestrel is a progestin. Suppresses gonadotropins (FSH, LH), inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
AVLAYAH is a combination of ethinyl estradiol and norgestimate. The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation. Norgestimate and its active metabolite norelgestromin bind to progesterone receptors in the cervix to thicken cervical mucus, impeding sperm penetration, and alter the endometrium.
1 tablet (0.1 mg levonorgestrel/0.02 mg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 placebo tablets).
500 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life is 12-14 hours; steady-state achieved within 3 days; clinical significance: dosing interval every 12 hours.
Terminal elimination half-life is approximately 2.5 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 50-60% as unchanged drug; Hepatic metabolism: 30-40% as inactive metabolites; Fecal: 10-20%.
Primarily renal excretion of unchanged drug (80-85%); biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Contraceptive (Hormonal)
Contraceptive (Hormonal)